This is a StreetInsider.com Premium Only Page

ContraFect (CFRX) – StreetInsider.com Reports

Nov 15, 2023 04:46 PM ContraFect (CFRX) Announces Restructuring, CEO Resigns

Oct 30, 2023 05:27 PM ContraFect (CFRX) Announces $15M Share Offering

Oct 24, 2023 04:12 PM ContraFect (CFRX) Announces 7.03M Share Offering by Selling Stockholders

Oct 16, 2023 07:30 AM ContraFect (CFRX) Announces FDA Clearance of CF-370 IND Application

Sep 18, 2023 07:31 AM ContraFect (CFRX) Announces Submission of IND Application to the FDA for CF-370

Jun 27, 2023 08:33 AM ContraFect (CFRX) Enters Warrant Exercise Transaction for Proceeds of $9.6M

Jun 8, 2023 04:35 PM ContraFect (CFRX) to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens

Apr 28, 2023 04:24 PM ContraFect (CFRX) Announces 7.03M Share Offering by Selling Stockholders

Apr 17, 2023 04:41 PM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.30%

Apr 13, 2023 07:46 AM Maxim Group Upgrades ContraFect Corp. (CFRX) to Buy

Mar 7, 2023 12:37 PM ContraFect (CFRX) received decision to grant European patent related to antibiotic combinations

Feb 28, 2023 08:31 AM ContraFect (CFRX) Prices $10M Share Offering at $4/sh, Announces Concurrent Private Placement

Feb 27, 2023 04:33 PM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.22%

Feb 27, 2023 09:47 AM ContraFect (CFRX) Resumes Trading Following Pause, Up 84%

Dec 19, 2022 04:31 PM ContraFect (CFRX) Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

Dec 13, 2022 08:05 AM ContraFect (CFRX) Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement

Nov 28, 2022 08:05 AM ContraFect (CFRX) Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Aug 15, 2022 08:25 AM ContraFect (CFRX) Reports Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity

Jul 14, 2022 08:52 AM Maxim Group Downgrades ContraFect Corp. (CFRX) to Hold

Jul 14, 2022 06:58 AM SVB Leerink Downgrades ContraFect Corp. (CFRX) to Market Perform

Jul 13, 2022 06:18 PM Cantor Fitzgerald Downgrades ContraFect (CFRX) to Neutral, Lowers PT to $1 from $15

Jul 13, 2022 04:06 PM ContraFect (CFRX) Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis

Jul 1, 2022 04:26 AM Stocks with Implied Volatility Movement

Jun 30, 2022 03:44 AM Stocks with Implied Volatility Movement

Jun 28, 2022 04:35 AM Stocks with Implied Volatility Movement

Jun 21, 2022 04:36 AM Stocks with Implied Volatility Movement

May 17, 2022 11:03 AM Mizuho Securities Reiterates ContraFect (CFRX) a Buy with $9 Price Target Ahead of Upcoming DISRUPT Study Readout

May 16, 2022 09:49 AM Cantor Fitzgerald Reiterates Overweight Rating. $15 Price Target on ContraFect (CFRX), "Expect Upwards Earnings Revision to Move Share Higher"

Apr 18, 2022 07:31 AM ContraFect (CFRX) Announces Presentations Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance

Mar 24, 2022 12:08 PM Cantor Fitzgerald Reiterates ContraFect (CFRX) at Overweight with $15 PT, Expects Upwards Earnings Revisions

Feb 2, 2022 08:13 AM WBB Securities Upgrades ContraFect Corp. (CFRX) to Buy

Dec 8, 2021 05:19 PM ContraFect (CFRX) Announces 8.82M Share Offering

Nov 15, 2021 11:12 AM ContraFect Corp. (CFRX) PT Lowered to $9 at Mizuho Securities

Oct 13, 2021 03:36 PM ContraFect (CFRX) received a Notice of Allowance for its US patent application 16/674,149 - Patent Grants

Sep 29, 2021 07:33 AM ContraFect (CFRX) Selected to Present Late Breaking Phase 2 Exebacase Data at IDWeek

Sep 9, 2021 06:24 AM SVB Leerink Starts ContraFect Corp. (CFRX) at Outperform

Jul 19, 2021 07:34 AM ContraFect (CFRX) Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID

May 3, 2021 07:32 AM ContraFect (CFRX) Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office

Apr 1, 2021 06:33 AM ContraFect Corp. (CFRX) PT Lowered to $10 at Mizuho Securities

Mar 31, 2021 11:42 AM ContraFect Corp. (CFRX) PT Lowered to $10 at Mizuho Securities, Keeps 'Buy'

Mar 31, 2021 10:35 AM WBB Securities Starts ContraFect Corp. (CFRX) at Speculative Buy

Mar 18, 2021 09:31 AM Pre-Open Stock Movers 03/18: (UPST) (TKAT) (SINO) Higher; (TBIO) (CFRX) (RIDE) Lower (more...)

Mar 18, 2021 06:03 AM ContraFect (CFRX) Prices 10M Share Common Offering at $5/Sh

Mar 17, 2021 05:40 PM After-Hours Stock Movers 03/17: (UPST) (WSM) (FIVE) Higher; (TBIO) (CFRX) (SLDB) Lower (more...)

Mar 17, 2021 04:01 PM ContraFect (CFRX) to Offer Common Stock

Mar 16, 2021 10:36 AM ContraFect Corp. (CFRX) PT Raised to $17.50 at Chardan Capital Markets

Mar 12, 2021 09:19 AM Pre-Open Stock Movers 03/12: (ANIX) (CRFX) (NVAX) Higher; (MRKR) (RIDE) (POSH) Lower (more...)

Mar 11, 2021 05:37 PM After-Hours Stock Movers 03/11: (CFRX) (NVAX) (FNKO) Higher; (MRKR) (POSH) (ULTA) Lower (more...)

Mar 11, 2021 04:08 PM ContraFect (CFRX) Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook

Mar 11, 2021 09:54 AM ContraFect (CFRX) awarded a $9.7M HHS research and development contract